BiotechTube

Letermovir 240 mg Oral Tablet

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infections, Cytomegalovirus

Conditions

Infections, Cytomegalovirus

Trial Timeline

Oct 1, 2023 → Apr 1, 2027

NCT ID
NCT06057194

About Letermovir 240 mg Oral Tablet

Letermovir 240 mg Oral Tablet is a phase 2 stage product being developed by Merck for Infections, Cytomegalovirus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06057194. Target conditions include Infections, Cytomegalovirus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06057194Phase 2Recruiting

Competing Products

20 competing products in Infections, Cytomegalovirus

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
25
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
VN-0200Daiichi SankyoPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
85
MicafunginAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 1
33
Micafungin + PlaceboAstellas PharmaPhase 3
77
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
GW810781ShionogiPhase 2
52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
CefiderocolShionogiPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85